New Dataset on State Laws Directing
Opioid Litigation Proceeds
|
|
Temple University’s Center for Public Health Law Research recently released their new State Laws Directing Opioid Litigation Proceeds dataset, published on PDAPS.org and created in partnership with the Legislative Analysis and Public Policy Association (LAPPA) with funding from the Office of National Drug Control Policy. The dataset examines key features of laws that direct the use of opioid litigation proceeds across all 50 states and the District of Columbia in effect as of August 1, 2022.
These data can be used to assess states’ progress in enacting the Opioid Litigation Proceeds Model Act, identify gaps in existing state laws, and demonstrate the utility of policy surveillance methods for assessing adherence and diffusion of model legislation.
PDAPS is an online resource developed by a team at the Center for Public Health Law Research at Temple University. These data were developed in partnership with the Legislative Analysis and Public Policy Association (LAPPA) with funding from the Office of National Drug Control Policy, Executive Office of the President.
Click here to explore the dataset.
|
|
Stream Season 4 of the JCOIN Aced It Podcast
|
|
|
Season 4 of the JCOIN Aced It Podcast is now streaming on Apple Podcasts, Spotify, and wherever you get your podcasts! As of this month, the podcast has surpassed 7,000 downloads.
The Aced It podcast is the place to go if you‘re trying to find out what‘s new in the health and justice research world, but don‘t have the time, energy, or know-how to decipher all that academic writing. Dr. Danielle Rudes and Shannon Magnuson from the Center for Advancing Correctional Excellence (ACE!) at George Mason University developed the Aced It! podcast to bring relevant research articles to a broader audience by putting them into layperson’s terms sharing the findings and implications in about 15 minutes.
Season 4 covers topics including stigma and substance use disorders, incarcerated individuals’ preference for medication assisted treatment, barriers to Medicaid access, and more! New episodes are released every Tuesday.
Click here to start listening.
|
|
JCOIN Funding Announcement:
Next J-RIG Application Cycle Closes February 15
|
|
|
|
The JCOIN Rapid Innovation Grant (J-RIG) program is a rapid-funding mechanism to support small grants to research newly emerging policies and practices, or to evaluate interventions that address prevention and treatment of addiction in justice settings. While opioids are an important priority for J-RIG projects, applications may focus more broadly on other substance use issues, particularly substances associated with overdose and overdose mortality. This cycle will prioritize grants concerning social determinants of health (especially housing and income) that affect treatment access and outcomes for people with justice system involvement. J-RIG is intended to facilitate short-term projects that are incompatible with traditional National Institutes of Health (NIH) funding mechanisms for various reasons, including, but not limited to, time sensitivity or collecting pilot data.
J-RIG welcomes applicants who do and do not work in research environments who could benefit from funding to study local initiatives, policy changes, or practice improvement efforts. J-RIG projects are appropriate for developmental pilots, feasibility studies, evaluation studies, or other research broadly defined as foundational work for further research and practice. J-RIG funding is not suitable for projects that will provide services but do not include a research or evaluation component.
Cycle 8: Proposals due February 15, 2023, by 11:59pm ET.
Click here for more information.
|
|
SAMHSA Announces National Survey on Drug Use and Health (NSDUH) Results Detailing Mental Illness and Substance Use Levels in 2021
|
|
Last week, the Substance Abuse and Mental Health Services Administration (SAMHSA) released the results of the 2021 National Survey on Drug Use and Health (NSDUH). The survey results provide information about how Americans report on their experience with mental health conditions, substance use, and treatment access.
The survey found that 16 percent of the U.S. population, more than 46 million individuals, met the DSM-5 criteria for having a substance use disorder (SUD) in the past year. Of those with SUDs, 94 percent reported that they did not receive any treatment for their condition in 2021.
Over half the U.S. population used tobacco, alcohol or an illicit drug in the past month. Alcohol was the most popular substance used by people in the U.S. – 47.5% of the population used alcohol, followed by 19% who used a tobacco product and 14.3% used an illicit drug in the last month. The majority of adults who reported ever having a SUD (72.2%) considered themselves in recovery.
Mental illness affected more than one in five U.S. adults in 2021 (22.8 percent), with 5.5 percent reporting a serious mental illness.
“Every year since 1971, this survey has given us a window into our nation’s mental health and substance use challenges and 2021 was no different. As the findings make clear, millions of Americans young and old faced mental health and substance use challenges—sometimes both at once—during the second year of the pandemic,” said HHS Secretary Xavier Becerra in a news release.
Since 1971, NSDUH has served as the primary source of statistical information on substance use and mental health in this country, and the 2021 report is the most comprehensive to date.
To learn more, click here.
|
|
CDC Call for Abstracts: Emerging Infectious Diseases Thematic Supplement
|
|
Emerging Infectious Diseases (EID) and the US Centers for Disease Control and Prevention (CDC) are inviting abstract submissions for a thematic supplement entitled “Justice System Involvement, Infectious Diseases, and Public Health,” with a target publication date in the fall of 2023.
Submissions should be scholarly in nature and offer a clear contribution to new scientific knowledge or public health practice. Submissions may examine data/public health surveillance, research, programs, and policy related to infectious diseases and intersecting public health issues among people who are incarcerated or otherwise justice-involved. Submissions should cover issues related to one or more of the following topics:
-
Infectious disease risks among people (including youth) who are justice-involved
-
Occupational infectious disease risks among staff or incarcerated people working in carceral settings
-
Infection prevention and control in correctional and detention facilities
-
Intersections of infectious diseases with other areas of public health concern related to people who are justice-involved
-
Public health interventions tailored for people who are justice-involved
-
and more!
To read the full Call for Abstracts, click here.
|
|
|
Additional Resources and Updates
|
|
|
JCOIN Research Publications and Articles
|
|
|
Brown University Clinical Research Center
Berk, J., Murphy, M., Kane, K., Chan, P., Rich, J., & Brinkley-Rubinstein, L. (2021). Initial SARS-CoV-2 Vaccination Uptake in a Correctional Setting: Cross-sectional Study. JMIRx med, 2(3), e30176. https://doi.org/10.2196/30176
Brinkley-Rubinstein, L., Peterson, M., Martin, R., Chan, P., & Berk, J. (2021). Breakthrough SARS-CoV-2 Infections in Prison after Vaccination. The New England journal of medicine, 385(11), 1051–1052. https://doi.org/10.1056/NEJMc2108479
Maner, M., LeMasters, K., Lao, J., Cowell, M., Nowotny, K., Cloud, D., & Brinkley-Rubinstein, L. (2021). COVID-19 in corrections: Quarantine of incarcerated people. PloS one, 16(10), e0257842. https://doi.org/10.1371/journal.pone.0257842
Coordination and Translation Center (CTC)
Cuellar, A. E., Ramezani, N., Breno, A., Johnson, J. E., & Taxman, F. S. (2022). Drivers of County Engagement in Criminal Justice-Behavioral Health Initiatives. Psychiatric services (Washington, D.C.), 73(6), 709–711. https://doi.org/10.1176/appi.ps.202100485
JCOIN Accelerator
Davoust, M., Grim, V., Hunter, A., Jones, D. K., Rosenbloom, D., Stein, M. D., & Drainoni, M. L. (2021). Examining the implementation of police-assisted referral programs for substance use disorder services in Massachusetts. The International journal on drug policy, 92, 103142. https://doi.org/10.1016/j.drugpo.2021.103142
|
|
Macmadu, A., Adams, J. W., Bessey, S. E., Brinkley-Rubinstein, L., Martin, R. A., Clarke, J. G., Green, T. C., Rich, J. D., & Marshall, B. D. L. (2021). Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study. The International journal on drug policy, 91, 102841. https://doi.org/10.1016/j.drugpo.2020.102841
Massachusetts Clinical Research Center
Donelan, C. J., Hayes, E., Potee, R. A., Schwartz, L., & Evans, E. A. (2021). COVID-19 and treating incarcerated populations for opioid use disorder. Journal of substance abuse treatment, 124, 108216. https://doi.org/10.1016/j.jsat.2020.108216
National Institute on Drug Abuse (NIDA)
Ducharme, L. J., Wiley, T. R. A., Mulford, C. F., Su, Z. I., & Zur, J. B. (2021). Engaging the justice system to address the opioid crisis: The Justice Community Opioid Innovation Network (JCOIN). Journal of substance abuse treatment, 128, 108307. https://doi.org/10.1016/j.jsat.2021.108307
Yale University Clinical Research Center
Malloy, G. S. P., Puglisi, L., Brandeau, M. L., Harvey, T. D., & Wang, E. A. (2021). Effectiveness of interventions to reduce COVID-19 transmission in a large urban jail: a model-based analysis. BMJ open, 11(2), e042898. https://doi.org/10.1136/bmjopen-2020-042898
|
|
|
Research Publications and Articles
|
|
|
Baxley, C., Borsari, B., Reavis, J. V., Manuel, J. K., Herbst, E., Becker, W., Pennington, D., Batki, S. L., & Seal, K. (2023). Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials. Addictive behaviors, 139, 107589. https://doi.org/10.1016/j.addbeh.2022.107589
Goldman-Mellor, S., Kaplan, M. S., & Qin, P. (2022). Mortality Risk Following Nonfatal Injuries With Alcohol Use Disorder Involvement: A One-Year Follow-Up of Emergency Department Patients Using Linked Administrative Data. Journal of studies on alcohol and drugs, 83(6), 879–887. https://doi.org/10.15288/jsad.21-00444
Iezzi, D., Caceres-Rodriguez, A., Chavis, P., & Manzoni, O. J. J. (2022). In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner. Translational psychiatry, 12(1), 501. https://doi.org/10.1038/s41398-022-02271-8
Lu, L., Yang, W., Zhao, D., Wen, X., Liu, J., Liu, J., & Yuan, K. (2022). Brain recovery of the NAc fibers and prediction of craving changes in person with heroin addiction: A longitudinal study. Drug and alcohol dependence, 243, 109749. Advance online publication. https://doi.org/10.1016/j.drugalcdep.2022.109749
Saffari, M., Chang, K. C., Chen, J. S., Chang, C. W., Chen, I. H., Huang, S. W., Liu, C. H., Lin, C. Y., & Potenza, M. N. (2022). Temporal associations between depressive features and self-stigma in people with substance use disorders related to heroin, amphetamine, and alcohol use: a cross-lagged analysis. BMC psychiatry, 22(1), 815. https://doi.org/10.1186/s12888-022-04468-z
Salapenka, I., Konakanchi, J. S., & Sethi, R. (2022). Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder. The primary care companion for CNS disorders, 24(6), 21cr03150. https://doi.org/10.4088/PCC.21cr03150
|
|
Shah, S., Schwenk, E. S., Sondekoppam, R. V., Clarke, H., Zakowski, M., Rzasa-Lynn, R. S., Yeung, B., Nicholson, K., Schwartz, G., Hooten, W. M., Wallace, M., Viscusi, E. R., & Narouze, S. (2023). ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Regional anesthesia and pain medicine, rapm-2022-104013. Advance online publication. https://doi.org/10.1136/rapm-2022-104013
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2022). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809
Wang, L., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2022). Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US. Molecular psychiatry, 10.1038/s41380-022-01903-1. Advance online publication. https://doi.org/10.1038/s41380-022-01903-1
Zsiros, E., Ricciuti, J., Gallo, S., Argentieri, D., Attwood, K., Ji, W., Hutson, A., Visco, P., Coffey, D., Riebandt, G., Mark, J., Varghese, A., Hess, S. M., Furlani, T., Fabiano, A., Hennon, M., Yendamuri, S., Kauffman, E. C., Wooten, K. E., Hicks, W. L., Jr, … de Leon-Casasola, O. (2023). Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use. JAMA oncology, 10.1001/jamaoncol.2022.6278. Advance online publication. https://doi.org/10.1001/jamaoncol.2022.6278
|
|
|
Funding & Other Opportunities
|
|
|
ECHO Learning Community for Implementing MAT at CCBHC’s Application Deadline
National Council for Mental Wellbeing
February 9
Data-informed Care and Advocacy in Addiction Treatment
National Council for Mental Wellbeing
February 9
Learning Community for Rural Jurisdictions
Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP)
February 14
|
|
|
|
